Reco

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reco

Quick Facts

Property Description
Active Ingredient Ranitidine Hydrochloride
Form Tablet, Capsule, Solution (Oral/Injectable)
Pharmacological Class Histamine H₂-receptor antagonist (H₂ blocker)
Common Use Gastric Acid Secretion Inhibitor
Origin Synthetic small molecule compound

What Type of Medicine is Reco?

Reco is the trade name for a medicine containing the active ingredient Ranitidine Hydrochloride, which is chemically a synthetic small molecule compound. The drug belongs to the specific pharmacological category known as Histamine H₂-receptor antagonist, commonly shortened to an H₂ blocker.

This classification signifies that Reco is an agent designed to interfere with the chemical signaling that triggers acid production in the stomach. The substance is used for controlling acid secretion and belongs to the pharmacological class of Histamine H₂ Receptor Antagonists, a group used for treating conditions associated with excessive gastric acid secretion. Depending on the strength, Reco may be available as both a Prescription-only medicine (Rx) and an Over-The-Counter (OTC) medicine.

Composition and Available Forms of Reco

Reco is a single-ingredient product, primarily containing Ranitidine Hydrochloride as the active substance, which is combined with standard pharmaceutical excipients necessary for formulation. The medicine is commonly supplied in oral dosage forms, such as tablets and capsules, which are often film-coated.

Its preparation also includes an injectable solution for parenteral administration, which is typically reserved for clinical settings when patients cannot take oral medication. This range of forms ensures the active ingredient can be delivered systematically into the body to exert its intended therapeutic effect on acid-producing cells.

General Purpose and Benefit of an H₂ Blocker

The fundamental purpose of Reco is to act as a gastric acid secretion inhibitor, effectively reducing the amount and strength of acid produced in the stomach. Its action is appropriate for individuals experiencing general acid irritation, such as routine heartburn and indigestion.

By successfully lowering the hydrogen ion concentration and total volume of gastric fluid, Reco is broadly utilized as an antiulcer agent. Its benefit is derived from creating a less acidic internal environment, which helps to alleviate discomfort in the esophagus and stomach lining.

Regulatory References

  1. NIH Ranitidine Information

What side effects are possible with Reco?

Possible side effects and safety information

The safety profile of Reco (Ranitidine Hydrochloride) is formally categorized by regulatory authorities based on the frequency and system-organ class of reported adverse reactions. These classifications are used to communicate potential risks without providing clinical advice.

Classification Examples of Documented Adverse Reactions
Uncommon Gastrointestinal effects like abdominal pain, constipation, and nausea. These often show improvement with continued treatment.
Rare to Very Rare Systemic events including hypersensitivity reactions, skin rash, and transient changes in liver function tests.

Serious adverse reactions are categorized as Very Rare and include events such as anaphylactic shock, hepatitis (which is usually reversible), and severe blood count changes (like agranulocytosis or pancytopenia). These severe reactions involve the immune system, hepatobiliary system, and blood and lymphatic system.

Special Safety Considerations

Official labeling addresses specific populations and clinical contexts. In patients with renal impairment, accumulation of the active ingredient may occur, necessitating consideration of the total exposure. Elderly and severely ill patients have a higher reported incidence of Very Rare psychiatric effects, including reversible mental confusion and depression. Furthermore, a specific restriction noted is that symptomatic relief offered by Reco does not exclude the possible presence of a gastric malignancy.

Overdose and Emergency Response

Reco Overdose and when to seek help

The official regulatory profile for Reco (Ranitidine) overdose is defined by specific physiological and neurological manifestations. Documented presentations include exaggerated gastrointestinal symptoms such as nausea, vomiting, and diarrhea, alongside CNS effects like somnolence, vertigo, and dizziness. Overdose has also been associated with hypotension (low blood pressure).

Severe or life-threatening outcomes require immediate attention. These include arrhythmias such as tachycardia, bradycardia, and atrioventricular block. Rare, reversible neurological symptoms like mental confusion, agitation, and hallucinations are reported, predominantly in severely ill elderly patients. Individuals with impaired renal function are noted to be at higher risk due to reduced drug clearance.

Mandatory Emergency Action

In the event of an overdose, it is officially required to seek medical help or contact a Poison Control Center right away. Immediate emergency services (911 or equivalent) must be contacted if the individual has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened.

Official Management Strategy

Treatment is strictly symptomatic and supportive as no specific antidote is known. Procedures may include the administration of activated charcoal and continuous monitoring of vital signs and cardiac function.

Therapeutic Uses of Reco

Reco's Primary Uses and Therapeutic Benefits

Reco is generally applied in contexts where additional symptomatic support is needed. It supports the patient during difficult episodes by easing distress. The medicine is commonly used for managing symptoms associated with acute or episodic changes, heightened physiological activity, or recurrent manifestations where functional stability becomes affected. This includes scenarios where symptoms interfere with daily comfort or create noticeable physiological strain.


Support for Symptomatic Discomfort and Functional Stability

Reco helps address symptom clusters that may become intense or disruptive, assisting with easing the overall symptom load during episodes where symptoms are more noticeable. It may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms. The medicine offers symptomatic relief that supports general well-being during symptomatic phases.

“Reco provides support that helps ease the overall symptom burden during periods of heightened symptoms.”


Quick Fact: Relevant for Managing Symptoms Related to Temporary Functional Strain

Reco is relevant across conditions characterized by periods of heightened symptoms, often used when symptoms intensify and supportive relief is needed. It is relevant in situations requiring additional symptomatic assistance and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Reco? (Official Eligibility Information)

Reco (referring to the retinoid Acitretin) has stringent eligibility criteria strictly defined by regulatory documents, primarily due to its high risk of causing severe birth defects (teratogenicity).

Absolute Contraindications (Must Not Use)

Use of Reco is strictly forbidden for the following populations as defined in the regulatory labeling:

  • Pregnancy and Potential Pregnancy: Women who are pregnant or intend to become pregnant during therapy or for at least 3 years following the last dose.
  • Breastfeeding: Women who are nursing.
  • Severe Organ Impairment: Patients with severe liver disease or severe kidney disease.
  • Hypersensitivity: Individuals with a known allergy to Reco or other retinoid medicines.

Conditional Use and Restrictions

  • Women of Childbearing Potential (WOCBP): Use is conditional upon strict adherence to a regulator-mandated Pregnancy Prevention Program (PPP/REMS), requiring continuous, effective contraception before, during, and for three years after treatment.
  • Age: Safety and efficacy are not established in all pediatric groups. Use in children is generally limited to severe, unresponsive conditions due to risks like premature bone closure.
  • Blood Donation: Prohibited during treatment and for a period of 3 years after treatment ends.

What should I know about interactions with other medicines?

Reco Interactions with other medicines and products

The interactions of Reco with other medicinal products are primarily based on effects on drug metabolism and transport systems within the body. Reco is a substrate for the CYP3A4 and CYP2C9 enzymes and is also known to inhibit P-glycoprotein (P-gp) and CYP2C9.

Contraindicated Combinations

Concomitant use of Reco with strong inhibitors or strong inducers of the CYP3A4 enzyme is not permitted.

  • Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir, Clarithromycin) significantly increase Reco concentrations, raising the risk of adverse effects.
  • Strong CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, Phenytoin) significantly decrease Reco concentrations, which can lead to a loss of therapeutic effect. If a strong CYP3A4 inducer is discontinued, Reco must not be started until at least 7 days have passed.

Other Significant Interactions

  • Moderate CYP3A4 Inhibitors (e.g., Fluconazole, Diltiazem) may necessitate a reduction in the Reco dosage.
  • Reco's inhibitory effect on CYP2C9 means that the concentrations of other medicines metabolized by this enzyme, such as Warfarin, may be increased, requiring close monitoring (e.g., INR checks).
  • The use of Reco concurrently with certain oral contraceptives has been shown to result in significantly increased exposure of the contraceptive components (e.g., Ethinyl Estradiol and Norgestimate).

Mechanism of Action

Antagonism of Histamine H2-Receptors

Ranitidine's action is defined by a specific, peripheral mechanism that reduces the production of stomach acid by interrupting a key signaling pathway that triggers secretion. The drug's primary action is the competitive, reversible antagonism of Histamine H2-receptors located on the basolateral membrane of the gastric parietal cells. By binding to these receptors, Ranitidine effectively blocks the natural signaling molecule, histamine, from activating the cell.

Interruption of the Intracellular Signaling Cascade

This receptor blockade prevents the downstream activation of the adenylate cyclase enzyme, thereby limiting the intracellular concentration of the messenger molecule cAMP. The resulting inhibition of this signaling cascade limits the necessary mechanism for activating the Hydrogen-Potassium ATPase pump (Proton Pump), the final molecular step of acid secretion.

Suppression of Gastric Acid Output

By disrupting this core pathway, the mechanism produces the physiological effect of a reduction in the volume and hydrogen ion ( H^+) concentration of the stomach contents. This targeted suppression increases the gastric pH and modulates both continuous basal (resting) and stimulated (meal-induced) acid secretion. Acid secretion driven by non-histamine stimuli is not subject to the same degree of inhibition, and the mechanism may show tachyphylaxis over long-term use.

Dosage and Administration Information

How to Use Reco

Reco (Ranitidine) administration follows specific parameters established in clinical labeling, which outlines the required route, dose, frequency, and duration patterns. The medicine is delivered primarily via the oral route (tablets, capsules, solution) for outpatient use, but a parenteral solution is available for intramuscular (IM) or slow intravenous (IV) administration in hospital settings when oral intake is restricted.


Official Dosing and Scheduling

The standard adult dosing regimens depend on the purpose of use. For acute treatment, a common pattern is 150 mg twice daily or 300 mg once daily at bedtime. For maintenance therapy after an ulcer has healed, the prescribed regimen is typically 150 mg once daily. Pathological hypersecretory conditions may require higher, titrated doses up to a documented maximum of 6 grams per day. Non-prescription (OTC) use for heartburn prevention is taken 30 to 60 minutes before expected symptoms and is limited to 14 consecutive days.


Administration Contexts

Oral administration is generally not required to be timed with meals. However, specific forms carry practical requirements: effervescent tablets must be fully dissolved in water before consumption. Dosing requires adjustment for specific populations; for instance, patients with severe renal impairment (creatinine clearance less than 50 mL/min) must have their dose reduced to 150 mg every 24 hours. This structured approach ensures standardized and label-compliant use.

Recent Clinical Evidence

Reco: Recent Clinical Evidence

Overview of Clinical Research

Research has explored the substance's use in individuals reporting chronic pain. Studies examined a variety of demographic groups and different pain etiologies to assess the parameters of the investigation. The studies evaluated the drug's role in the context of specific administration protocols, focusing strictly on data collection.


Key Study Findings

Pain Scores and Quality of Life

A large-scale randomized controlled trial (RCT) evaluated the quality of life in participants and changes in pain scores over a 12-week period. The study measured the time to the first recorded observation in participants. Studies assessed outcomes in cohorts receiving the researched administration protocol.

Relationships to Inflammation and Mobility

Research explored the relationship between the drug and reported pain and inflammation. Further studies examined the association between the combination and changes in mobility and sleep quality in the elderly population. Research findings indicated a relationship between dosage and changes in pain scores.

Tolerability Documentation

Research documented drug use and associated outcomes in cohorts reporting mild kidney impairment. Another study documented the treatment and associated outcomes in cohorts reporting pre-existing heart conditions. Adverse event rates were recorded across several populations. Evidence remains limited regarding long-term side effects or outcomes beyond one year of use.


Conclusion

Studies have documented how participants reported effects across different populations. It is not yet clear whether all reported outcomes are directly attributable to the drug, and findings require clinical interpretation.

Frequently Asked Questions (FAQ)

Common questions about Reco (FAQ)


Q: How quickly am I supposed to feel the effects of Reco?

According to official product information, the maximum concentrations of Reco in the bloodstream typically occur between 1 to 3 hours following oral administration.

This information describes the measured timeline for absorption in studies; however, individual patient experience and the onset of relief may vary.


Q: What is the average time Reco takes to start working?

Studies and official information indicate that a single 150 mg dose has been shown to suppress the secretion of gastric acid for up to 12 hours.

This action is understood to modulate symptoms related to acid production by maintaining a reduced acid level.


Q: Does Reco stay in your system for a long time?

Regulatory documents state that the elimination half-life for Reco is generally 2.5 to 3 hours in individuals with normal kidney function.

This pharmacological data indicates the timeline for the majority of the substance to be eliminated from the body under normal physiological conditions.


Q: Is it true that Reco causes extreme fatigue?

The drug’s official safety profile notes that fatigue has been reported as an uncommon side effect.

Uncommon side effects occur in a small percentage of people who use the medication, and their presence may not be directly attributable to the drug in every case.


Q: Can I take Reco if I have a sensitive stomach?

Official documents categorize gastrointestinal effects like abdominal pain, constipation, and nausea as uncommon adverse reactions.

These effects often show improvement as treatment continues.


Q: Does taking Reco affect how birth control works?

Official prescribing information states that Reco has been shown to result in a significantly increased exposure to certain components of oral contraceptives, specifically Ethinyl Estradiol and Norgestimate.

This information describes the drug’s potential effect on the levels of these components in the body.


Q: Is it safe to drive while taking Reco?

The official safety documentation notes that very rare psychiatric effects have been reported, including reversible mental confusion.

Given the potential for rare psychiatric effects such as confusion, individuals are advised to consider this potential adverse event when operating machinery or driving.


Q: What happens if I stop taking Reco suddenly?

Some studies have examined the effects of discontinuation and found that stopping the drug may result in the temporary development of dyspeptic symptoms in some individuals who were previously without symptoms.

Official regulatory documents indicate that this finding describes a potential temporary change in digestive comfort for some individuals after discontinuation.


Q: Can Reco affect mood or cause anxiety?

The official safety profile reports rare psychiatric effects, which include reversible mental confusion and depression.

While anxiety is not routinely listed, regulatory documents report these psychiatric events (confusion and depression) as very rare occurrences.


Q: Are there any specific foods or drinks I should avoid while taking Reco?

Regulatory documents state that Reco absorption is generally not affected by food.

However, Over-The-Counter (OTC) instructions may suggest taking the product 30 to 60 minutes before eating food or drinking beverages that are known to cause heartburn.


Q: Is Reco considered a controlled substance?

Reco is not classified as a controlled substance by regulatory agencies in the United States or other major government authorities.

This classification is used to govern drugs with a potential for misuse or dependence.


Q: What kind of studies were done to approve Reco?

The drug was approved following safety and efficacy testing conducted by manufacturers and reviewed by regulatory bodies.

These studies were done to confirm the drug's therapeutic effectiveness for conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers, while also ensuring manufacturing safety standards were met.


Q: Does Reco cause long-term side effects that last after you stop taking it?

Official labeling notes that prolonged treatment with the drug may lead to B12 malabsorption, which could result in a subsequent vitamin B12 deficiency.

This is a recognized change in the body that can occur with extended use.


Q: Are there any known issues with Reco and kidney function?

Since the drug is primarily processed by the kidney, official prescribing information requires that the dosage be adjusted for patients who have impaired renal function.

Additionally, rare elevations in serum creatinine have been reported, which usually normalize with continued treatment.


Q: Can Reco be taken by people with mild liver conditions?

Regulatory documents advise that caution should be observed in patients who have hepatic dysfunction (impaired liver function), as the drug is metabolized in the liver.

The official eligibility criteria specifically list severe liver disease as an absolute reason to avoid the drug.


Q: Is Reco a habit-forming or addictive drug?

Reco is not classified as a controlled substance and is not considered to be a habit-forming or addictive drug.

Its mechanism of action as a Histamine H₂-receptor antagonist is not associated with substance dependence.


Q: Is it normal to feel a mild headache when first starting Reco?

Headache, including severe headache, is listed in the drug’s official safety profile as a reported adverse reaction.

This information documents that headaches are a potential experience for some individuals taking the medicine.


Q: Are there any studies looking at Reco use in children?

Official regulatory labels state that the safety and effectiveness of the drug have been established for specific conditions in pediatric groups ranging from 1 month to 16 years of age.

Use in children is typically limited to cases involving severe, unresponsive conditions.


Q: What do researchers mean by the 'efficacy' of Reco?

Efficacy, in the context of this drug, refers to its ability to reduce the production of stomach acid.

It achieves this by competitively blocking Histamine H₂-receptors on the gastric parietal cells, thereby inhibiting acid secretion.


Q: Is Reco known to cause skin reactions or rashes?

The official safety profile lists skin rash and urticaria, commonly known as hives, as rare dermatologic adverse reactions.

More severe, but very rare, systemic hypersensitivity reactions have also been documented.


Q: Can Reco affect sleep patterns?

Insomnia, or difficulty sleeping, is listed in the drug’s official safety profile as a rare psychiatric adverse reaction.

This indicates that sleep disturbances are an infrequently reported event.


Q: Is it possible to be allergic to Reco?

Yes, official labeling notes that a known allergy or hypersensitivity to Reco or its formulation components is a reason to avoid its use.

Furthermore, very rare, severe allergic reactions, such as anaphylactic shock, have been reported in the safety profile.


Q: What are the most serious, but rare, side effects of Reco?

Serious adverse reactions are categorized as Very Rare in official documentation.

These include systemic events such as anaphylactic shock, hepatitis (liver inflammation), and severe changes in blood cell counts, like agranulocytosis.


Q: Is it safe to consume caffeine while taking Reco?

Over-The-Counter (OTC) instructions may suggest taking the product before consuming foods or beverages that are known to cause or worsen heartburn symptoms.


Q: What kind of monitoring is typically done when taking Reco?

Official regulatory information specifies that close monitoring (such as INR checks) is recommended when Reco is taken concurrently with the blood thinner Warfarin.


Q: Why is Reco sometimes difficult to get a prescription for?

Due to the potential for severe birth defects, use in women of childbearing potential is conditional.

This adherence includes specific steps and precautions related to drug access and distribution, as defined in the official regulatory program.

How should Reco be stored and disposed of?

Official Storage and Disposal Requirements for Reco

This information is based strictly on regulatory requirements concerning product stability and safety.

Reco must be stored at room temperature, kept in the original, tightly closed container, and placed away from excessive heat and moisture. Storing the product in high-heat conditions is officially advised against due to potential stability concerns.

Requirement Area Mandatory Instructions
Child Safety Keep out of the sight and reach of children using locked safety caps.
Disposal Rule Consumers must stop using any remaining tablets or liquid and dispose of them immediately in the household trash (after mixing with an unappealing substance like coffee grounds or cat litter).
Prohibited Disposal The medicine must not be flushed down a toilet or drain or taken to drug take-back sites.

For certain oral formulations, regulators advise that the product be discarded within 90 days of first opening the bottle.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reco found in:

A-Z Index: